Discovery of BMS-986160 as a second-generation inhibitor of the hepatitis C virus NS3/4A with pan-genotypic antiviral activity

被引：0
|
作者：
Sun, Li-Qiang [1 ]
Mull, Eric [3 ]
Kandhasamy, Sarkunam [2 ]
Baratam, Venkata Rao [2 ]
Puttaswamy, Sunitha [2 ]
Pulicharla, Nagalakshmi [2 ]
Vishwakrishnan, Sureshbabu [2 ]
Reddy, Subba [2 ]
Trivedi, Ravi [2 ]
Sinha, Sarmistha [2 ]
Sivaprasad, Sankar [2 ]
Rao, Abhijith [2 ]
Desai, Salil [2 ]
Ghosh, Kaushik [2 ]
Rajamani, Ramkumar [1 ]
Wang, Ying-Kai [3 ]
Fang, Hua [3 ]
Mathur, Arvind [1 ]
Rampulla, Richard [1 ]
Jenkins, Susan [3 ]
Meanwell, Nicholas [1 ]
McPhee, Fiona [3 ]
Scola, Paul [3 ]
机构：
[1] Bristol Myers Squibb Res & Dev, Princeton, NJ USA
[2] Biocon Bristol Myers Squibb R&D Ctr, Bangalore, Karnataka, India
[3] Bristol Myers Squibb Res & Dev, Wallingford, CT USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2019年 / 258卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
42-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
    Lawitz, Eric
    Sulkowski, Mark
    Jacobson, Ira
    Kraft, Walter K.
    Maliakkal, Benedict
    Al-Ibrahim, Mohamed
    Gordon, Stuart C.
    Kwo, Paul
    Rockstroh, Juergen Kurt
    Panorchan, Paul
    Miller, Michelle
    Caro, Luzelena
    Barnard, Richard
    Hwang, Peggy May
    Gress, Jacqueline
    Quirk, Erin
    Mobashery, Niloufar
    ANTIVIRAL RESEARCH, 2013, 99 (03) : 214 - 220
  • [42] Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure
    Rudd, Michael T.
    McCauley, John A.
    Butcher, John W.
    Romano, Joseph J.
    McIntyre, Charles J.
    Nguyen, Kevin T.
    Gilbert, Kevin F.
    Bush, Kimberly J.
    Holloway, M. Katharine
    Swestock, John
    Wan, Bang-Lin
    Carroll, Steven S.
    DiMuzio, Jillian M.
    Graham, Donald J.
    Ludmerer, Steven W.
    Stahlhut, Mark W.
    Fandozzi, Christine M.
    Trainor, Nicole
    Olsen, David B.
    Vacca, Joseph P.
    Liverton, Nigel J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (03): : 207 - 212
  • [43] The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
    Scola, Paul M.
    Sun, Li-Qiang
    Wang, Alan Xiangdong
    Chen, Jie
    Sin, Ny
    Venables, Brian L.
    Sit, Sing-Yuen
    Chen, Yan
    Cocuzza, Anthony
    Bilder, Donna M.
    D'Andrea, Stanley V.
    Zheng, Barbara
    Hewawasam, Piyasena
    Tu, Yong
    Friborg, Jacques
    Falk, Paul
    Hernandez, Dennis
    Levine, Steven
    Chen, Chaoqun
    Yu, Fei
    Sheaffer, Amy K.
    Zhai, Guangzhi
    Barry, Diana
    Knipe, Jay O.
    Han, Yong-Hae
    Schartman, Richard
    Donoso, Maria
    Mosure, Kathy
    Sinz, Michael W.
    Zvyaga, Tatyana
    Good, Andrew C.
    Rajamani, Ramkumar
    Kish, Kevin
    Tredup, Jeffrey
    Klei, Herbert E.
    Gao, Qi
    Mueller, Luciano
    Colonno, Richard J.
    Grasela, Dennis M.
    Adams, Stephen P.
    Loy, James
    Levesque, Paul C.
    Sun, Huabin
    Shi, Hong
    Sun, Lucy
    Warner, William
    Li, Danshi
    Zhu, Jialong
    Meanwell, Nicholas A.
    McPhee, Fiona
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (05) : 1730 - 1752
  • [44] Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors
    Raboisson, Pierre
    Lin, Tse-I
    de Kock, Herman
    Vendeville, Sandrine
    de Vreken, Wim Van
    McGowan, David
    Tahri, Abdellah
    Hu, Lili
    Lenz, Oliver
    Delouvroy, Frederic
    Surleraux, Dominique
    Wigerinck, Piet
    Nilsson, Magnus
    Rosenquist, Asa
    Samuelsson, Bertil
    Simmen, Kenneth
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (18) : 5095 - 5100
  • [45] NS3 peptide, a novel potent hepatitis C virus NS3 helicase inhibitor:: Its mechanism of action and antiviral activity in the replicon system
    Gozdek, Agnieszka
    Zhukov, Igor
    Polkowska, Agnieszka
    Poznanski, Jaroslaw
    Stankiewicz-Drogon, Anna
    Pawowicz, Jerzy M.
    Zagorski-Ostoja, Wodzirnierz
    Borowski, Peter
    Boguszewska-Chachulska, Anna M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) : 393 - 401
  • [46] Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir
    Susser, Simone
    Flinders, Mathieu
    Reesink, Henk W.
    Zeuzem, Stefan
    Lawyer, Glenn
    Ghys, Anne
    Van Eygen, Veerle
    Witek, James
    De Meyer, Sandra
    Sarrazin, Christoph
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (05) : 2746 - 2755
  • [47] In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
    Lenz, Oliver
    Verbinnen, Thierry
    Lin, Tse-I
    Vijgen, Leen
    Cummings, Maxwell D.
    Lindberg, Jimmy
    Berke, Jan Martin
    Dehertogh, Pascale
    Fransen, Els
    Scholliers, Annick
    Vermeiren, Katrien
    Ivens, Tania
    Raboisson, Pierre
    Edlund, Michael
    Storm, Susan
    Vrang, Lotta
    de Kock, Herman
    Fanning, Gregory C.
    Simmen, Kenneth A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 1878 - 1887
  • [48] Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates
    Lopez-Labrador, F. Xavier
    Moya, Andres
    Gonzalez-Candelas, Fernando
    ANTIVIRAL THERAPY, 2008, 13 (04) : 481 - 494
  • [49] Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
    Venkatraman, Srikanth
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 289 - 294
  • [50] Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease
    Skorenski, Marcin
    Pachota, Magdalena
    Pyrc, Krzysztof
    Sienczyk, Marcin
    Oleksyszyn, Jozef
    ANTIVIRAL RESEARCH, 2017, 144 : 286 - 298
12345